205 related articles for article (PubMed ID: 11801706)
1. Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer.
Shankar LK; Yamamoto AJ; Alavi A; Mandel SJ
J Nucl Med; 2002 Jan; 43(1):72-6. PubMed ID: 11801706
[TBL] [Abstract][Full Text] [Related]
2. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer.
Mandel SJ; Shankar LK; Benard F; Yamamoto A; Alavi A
Clin Nucl Med; 2001 Jan; 26(1):6-9. PubMed ID: 11139058
[TBL] [Abstract][Full Text] [Related]
3. Differentiated thyroid carcinoma: Incremental diagnostic value of
Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
[TBL] [Abstract][Full Text] [Related]
5. Neck and whole-body scanning with 5-mCi dose of (123)I as diagnostic tracer in patients with well-differentiated thyroid cancer.
Gulzar Z; Jana S; Young I; Bukberg P; Yen V; Naddaf S; Abdel-Dayem HM
Endocr Pract; 2001; 7(4):244-9. PubMed ID: 11497474
[TBL] [Abstract][Full Text] [Related]
6. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer.
Grewal RK; Tuttle RM; Fox J; Borkar S; Chou JF; Gonen M; Strauss HW; Larson SM; Schöder H
J Nucl Med; 2010 Sep; 51(9):1361-7. PubMed ID: 20720058
[TBL] [Abstract][Full Text] [Related]
7. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
Dam HQ; Kim SM; Lin HC; Intenzo CM
Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
[TBL] [Abstract][Full Text] [Related]
8. 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging.
Spanu A; Solinas ME; Chessa F; Sanna D; Nuvoli S; Madeddu G
J Nucl Med; 2009 Feb; 50(2):184-90. PubMed ID: 19164225
[TBL] [Abstract][Full Text] [Related]
9. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
[TBL] [Abstract][Full Text] [Related]
10. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 99mTc-methoxyisobutyl isonitrile and 201Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy.
Seabold JE; Gurll N; Schurrer ME; Aktay R; Kirchner PT
J Nucl Med; 1999 Sep; 40(9):1434-40. PubMed ID: 10492361
[TBL] [Abstract][Full Text] [Related]
12. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.
Oyen WJ; Verhagen C; Saris E; van den Broek WJ; Pieters GF; Corsten FH
J Nucl Med; 2000 Apr; 41(4):643-6. PubMed ID: 10768565
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostic scintigraphy and effectiveness of 131I radioiodine therapy in differentiated thyroid carcinoma (DTC)].
Bałdys-Waligórska A; Buziak-Bereza M; Huszno B; Wilczak A
Endokrynol Pol; 2006; 57(4):380-5. PubMed ID: 17006840
[TBL] [Abstract][Full Text] [Related]
14. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
15. Surveillance of patients to detect recurrent thyroid carcinoma.
Grigsby PW; Baglan K; Siegel BA
Cancer; 1999 Feb; 85(4):945-51. PubMed ID: 10091774
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the efficacy of iodine-131 for thyroid ablation.
Comtois R; Thériault C; Del Vecchio P
J Nucl Med; 1993 Nov; 34(11):1927-30. PubMed ID: 8229236
[TBL] [Abstract][Full Text] [Related]
17. 123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post 131I therapy whole body scanning.
Alzahrani AS; Bakheet S; Al Mandil M; Al-Hajjaj A; Almahfouz A; Al Haj A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5294-300. PubMed ID: 11701695
[TBL] [Abstract][Full Text] [Related]
18. Clinical usefulness of fusion of 131I SPECT and CT images in patients with differentiated thyroid carcinoma.
Yamamoto Y; Nishiyama Y; Monden T; Matsumura Y; Satoh K; Ohkawa M
J Nucl Med; 2003 Dec; 44(12):1905-10. PubMed ID: 14660715
[TBL] [Abstract][Full Text] [Related]
19. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?
Fatourechi V; Hay ID; Mullan BP; Wiseman GA; Eghbali-Fatourechi GZ; Thorson LM; Gorman CA
Thyroid; 2000 Jul; 10(7):573-7. PubMed ID: 10958309
[TBL] [Abstract][Full Text] [Related]
20. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.
Silberstein EB
J Nucl Med; 2007 Jul; 48(7):1043-6. PubMed ID: 17574976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]